FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer

Gareth O Griffiths, Sarah Burns, Simon I Noble, Fergus R Macbeth, David Cohen, Timothy S Maughan, Gareth O Griffiths, Sarah Burns, Simon I Noble, Fergus R Macbeth, David Cohen, Timothy S Maughan

Abstract

Background: Venous thromboembolism (VTE) occurs when blood clots in the leg, pelvic or other deep vein (deep vein thrombosis) with or without transport of the thrombus into the pulmonary arterial circulation (pulmonary embolus). VTE is common in patients with cancer and is increased by surgery, chemotherapy, radiotherapy and disease progression. Low molecular weight heparin (LMWH) is routinely used to treat VTE and some evidence suggests that LMWH may also have an anticancer effect, by reduction in the incidence of metastases. The FRAGMATIC trial will assess the effect of adding dalteparin (FRAGMIN), a type of LMWH, to standard treatment for patients with lung cancer.

Methods/design: The study design is a randomised multicentre phase III trial comparing standard treatment and standard treatment plus daily LMWH for 24 weeks in patients with lung cancer. Patients eligible for this study must have histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-small cell) within 6 weeks of randomisation, be 18 or older, and must be willing and able to self-administer 5000 IU dalteparin by daily subcutaneous injection or have it administered to themselves or by a carer for 24 weeks. A total of 2200 patients will be recruited from all over the UK over a 3 year period and followed up for a minimum of 1 year after randomisation. Patients will be randomised to one of the two treatment groups in a 1:1 ratio, standard treatment or standard treatment plus dalteparin. The primary outcome measure of the trial is overall survival. The secondary outcome measures include venous thrombotic event (VTE) free survival, serious adverse events (SAEs), metastasis-free survival, toxicity, quality of life (QoL), levels of breathlessness, anxiety and depression, cost effectiveness and cost utility.

Trial registration: Current Controlled Trials ISRCTN80812769.

Figures

Figure 1
Figure 1
Trial Schema.

References

    1. Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales. London, Stationary Office; 2001.
    1. Alberg AJ, Samet JM. Epidemiology of Lung Cancer. Chest. 2003;123S:21–49. doi: 10.1378/chest.123.1_suppl.21S.
    1. Samet JM. The epidemiology of lung cancer. Chest. 1993;103:20–25.
    1. Alifano M, Benedetti G, Trisolini R. Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer?: an urgent call for research. Chest. 2004;126:601–607. doi: 10.1378/chest.126.2.601.
    1. Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg. Is there a "high risk" group? American Journal of Surgery. 1970;120:527–530. doi: 10.1016/S0002-9610(70)80023-X.
    1. Kakkar AK, de Lorenzo F, Pineo GF, Williamson RC. Venous thrombosis and cancer. Baillieres Clin Haematol. 1998;11:675–687. doi: 10.1016/S0950-3536(98)80089-9.
    1. Kakkar AK, Williamson RC. Antithrombotic therapy in cancer. BMJ. 1999;318:1571–1572.
    1. Lee AY, Levine MN. Venous Thromboembolism and Cancer: Risks and Outcomes. Circulation. 2003;107:17–21. doi: 10.1161/01.CIR.0000047062.03282.A3.
    1. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978;5:1–26.
    1. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Journal of Clinical Oncology. 1999;11:105–110. doi: 10.1053/clon.1999.9023.
    1. Levitan N, Dowlatic A, Remick SC, Tahsilda HI, Sivinski LD, Beyth R, Rimm AA. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78:285–291. doi: 10.1097/00005792-199909000-00001.
    1. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Olsson CG, Turpie AG. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagulation Fibrinolysis. 2003;14:341–346. doi: 10.1097/00001721-200306000-00004.
    1. Buccheri G, Ferrigno D, Ginardi C, Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer. 1998;33:50–55. doi: 10.1016/S0959-8049(96)00310-3.
    1. Seitz R, Heidtmann HH, Wolf M, Immel A, Egbring R. Prognostic impact of an activation of coagulation in lung cancer. Ann Oncol. 1997;9:1255–1256. doi: 10.1023/A:1008477616923.
    1. Sorensen HT, Mellemkjaer L, Olsen JH, Nielsen GL. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850. doi: 10.1056/NEJM200012213432504.
    1. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Math M, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. doi: 10.1056/NEJMoa025313.
    1. Wolf RA. Are patients with cancer receiving adequate thromboprophylaxis? results from FRONTLINE. Cancer Treat Rev. 2003;29:7–9. doi: 10.1016/S0305-7372(03)80002-6.
    1. Kirwan CC. Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey. BMJ. 2003;327:597–598. doi: 10.1136/bmj.327.7415.597.
    1. Donati M. Cancer and thrombosis: from Phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995;74:278–281.
    1. Mousa S. Anitcoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost. 2002;28:45–52. doi: 10.1055/s-2002-20559.
    1. Gouin-Thibault I, Samama MM. Laboratory analysis of the thrombophilic state in cancer patients. Semin Thromb Hemost. 1999;25:167–172. doi: 10.1055/s-2007-994918.
    1. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999;25:173–182. doi: 10.1055/s-2007-994919.
    1. Bromberg M, Capello M. Cancer and blood coagulation: molecular aspects. Cancer J Sci Am. 1999;5:132–138.
    1. Zacharski L, Ornstein D. Heparin and cancer. Thromb Haemost. 1998;80:10–23.
    1. Kakkar AK, Hedges AR, Williamson RCN, Kakkar VV. Perioperative herparin therapy inhibits late death from metastatic cancer. Int J Oncol. 1995;6:885–888.
    1. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer "Petit Cellules" Group. Cancer. 1994;74:38–45. doi: 10.1002/1097-0142(19940701)74:1<38::AID-CNCR2820740108>;2-E.
    1. Altinbas M, Coskun HS, Er O. A randomised clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271. doi: 10.1111/j.1538-7836.2004.00871.x.
    1. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RCN. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol. 2004;22:1944–1948. doi: 10.1200/JCO.2004.10.002.
    1. Hejna M, Raderer M, Zielinski CC. Inhibition of metastases by anticoagulants. J Nati Cancer Inst. 1999;91:22–36. doi: 10.1093/jnci/91.1.22.
    1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565–1574.
    1. Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997;78:672–677.
    1. Folkman J. Seminars in medicine of the Beth Israel Hospital in Boston. N Engl J Med. 1995;333:1757–1763. doi: 10.1056/NEJM199512283332608.
    1. Bennett MR, Evan GI, Newby AC. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res. 1994;74:525–536.
    1. Wang A, Templeton DM. Inhibition of mitogenesis and c-fos induction in mesanglial cells by heparin and heparin sulfates. Kidney Int. 1996;49:437–438. doi: 10.1038/ki.1996.63.
    1. Mousa S. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev. 2002;20:163–180.
    1. Mousa A, Mohamed S. Antiangiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anticancer efficacy. Oncol Rep. 2004;12(4):683–688.
    1. Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003;1:2110–2115. doi: 10.1161/01.ATV.0000090671.56682.D7.
    1. Vlodavsky I, Ishai-Michaeli R, Mohsen M, Bar-Shavit R, Catane R, Ekre HP, Svahn CM. Modulation of neovasculaization and metastasis by species of heparin. Adv Exp Med Biol. 1992;313:317–327.
    1. Ekre HP, Naparstek Y, Lider O, Hyden P, Hagermark O, Nilsson T, Vlodavsky I, Cohen I. Anti-inflammatory effects of heparin and its derivatives: inhibition of complement and of lymphocyte migration. Adv Exp Med Biol. 1992;313:329–340.
    1. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2,500 versus 5,000 XaI units in 2070 patients. Br J Surg. 1995;82:496–501. doi: 10.1002/bjs.1800820421.
    1. Royston A, Babiker A. A menu driven facility for complex sample size calculation in randomised controlled trials with a survival or a binary outcome. Stata Journal. 2002;2:151–163.
    1. Dunn G, Maracy M, Dowrick C, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V. Estimating psychological treatment effects from a randomised controlled trial with both non-compliance and loss to follow up. British Journal of Psychiatry. 2003;183:323–331. doi: 10.1192/bjp.183.4.323.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться